Positive Phase III data has sent shares in Danish vaccine specialist Bavarian Nordic (OMX: BAVA) up 4% in Copenhagen this morning, following news that the firm’s second Phase III study of Imvamune smallpox vaccine met both primary endpoints.
The study of the investigational non-replicating smallpox vaccine compared efficacy with ACAM2000, the current US-licensed option, which is of the replicating vaccine type.
The company is developing the vaccine for those who cannot receive traditional replicating vaccines, such as people with atopic dermatitis and HIV.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze